PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Recently, data from the WELCOME trial revealed that in patients with NAFLD the PNPLA3 148M/M genotype was associated with higher liver fat percentage and lower DHA tissue enrichment and reduced amelioration of aminotransferases after DHA+EPA supplementation for 15–18 months [98].